Antigen News and Research

RSS

Genticel provides update on patents granted in the USA and Asia

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, provides an update on patents that have recently enriched its intellectual property estate.

25 Jul 2014

Immune system play role in memory impairment associated with chronic epilepsy

Could the body's own immune system play a role in memory impairment and cognitive dysfunction associated with conditions like chronic epilepsy, Alzheimer's dementia and concussions? Cleveland Clinic researchers believe so, based on a study published online by PLOS ONE.

25 Jul 2014

Prognostic value of visceral plural invasion limited in part-solid lung cancer

Visceral plural invasion is a significant predictor of survival in patients with small solid lung tumours but not in patients with part-solid tumours, Japanese study findings indicate.

23 Jul 2014

Iowa researchers develop vaccine to combat dust-mite allergies

Researchers at the University of Iowa have developed a vaccine that can combat dust-mite allergies by naturally switching the body's immune response.

23 Jul 2014

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest.

23 Jul 2014

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

23 Jul 2014

Chemclin's HIV kits for in-vitro qualitative determination of Anti-HIV 1+2

Chemclin's HIV kits are available for in-vitro qualitative determination of Antibody to Human Immunodeficiency Virus Type 1 and Type 2 (Anti-HIV 1+2) and P24 antigen of HIV in human serum or plasma by a sandwich chemiluminescent assay method.

22 Jul 2014

Chemclin's Anti-TP assay provides components for in-vitro qualitative determination of Anti-TP

Chemclin's Anti-TP assay provides components for in-vitro qualitative determination of Antibody to Treponema Pallidum (Anti-TP) in human serum or plasma by a double - antigen sandwich chemiluminescent assay method.

22 Jul 2014

Epigenetic test helps eliminate unnecessary repeat prostate biopsies

More than one million prostate biopsies are performed each year in the U.S. alone, including many repeat biopsies for fear of cancer missed. Therefore there is a need to develop diagnostic tests that will help avoid unnecessary repeat biopsies.

22 Jul 2014

Beckman announces national availability of Prostate Health Index

Beckman Coulter Diagnostics, a global leader in prostate cancer diagnostics, announces national availability of the Prostate Health Index (phi)*, a simple, non‐invasive blood test that is three times more specific in detecting prostate cancer1 than PSA (prostate‐specific antigen).

22 Jul 2014

Sixteen cores better than 12 for prostate cancer detection

Sixteen-core prostate biopsy has a slightly higher cancer detection rate than 12-core biopsy, but with a similar safety profile and no increased detection of clinically insignificant tumours, study findings show.

21 Jul 2014

Researchers release evidence substantiating unexpected dual role of immune system

University of Leicester researchers have released evidence substantiating an unexpected dual role of an important component of the immune system.

17 Jul 2014

Researchers develop world's first T-cell peptide-based vaccine for heart disease

Researchers at Wayne State University have made a fundamental discovery and, in subsequent collaboration with scientists at La Jolla Institute for Allergy and Immunology (LIAI), are one step closer to the goal of developing the world's first T-cell peptide-based vaccine for heart disease - the number one killer in the nation.

17 Jul 2014

Robot-assisted surgery to control prostate cancer effective in controlling disease for 10 years

Robot-assisted surgery to remove cancerous prostate glands is effective in controlling the disease for 10 years, according to a new study led by researchers at Henry Ford Hospital.

17 Jul 2014

Localised inflammation found in eosinophilic otitis media

Antigen-specific immunoglobulin E is produced locally in the middle ear mucosa of patients with eosinophilic otitis media, clinical research indicates.

15 Jul 2014

Researchers describe innovative technique for early disease detection

Despite impressive medical strides, cancer remains a leading killer and overwhelming burden to healthcare systems, causing well over a half million fatalities per year with a projected cost of $174 billion by 2020, according to the National Cancer Institute.

15 Jul 2014

New gene therapy may be effective for fighting fungal infections in cancer patients

Sleeping Beauty and fungal infections - not two items one would normally associate together, but for immunocompromised cancer patients they may prove to be a helpful combination.

9 Jul 2014

Researchers identify new genes that likely contribute to asthma

In a study published yesterday in the scientific journal Nature Immunology, a group at the La Jolla Institute (LJI) led by Pandurangan Vijayanand, Ph.D. identify new genes that likely contribute to asthma, a disease that currently affects over 200 million people world wide.

8 Jul 2014

Novel cancer immunotherapy for dogs could benefit humans as well

As in humans, cancers in dogs have complex causes. The interaction of the environment, food, and genetic disposition are the most well known factors. Today nearly all methods of human medicine are basically available for dogs with cancer, but this was not true of cancer immunotherapy so far.

8 Jul 2014

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014